Treatment of Hodgkin's disease and other malignant lymphomas.
D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009588:Nitrogen Mustard Compounds; D009607:Nitrosourea Compounds; D002699:Chlorambucil; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D002330:Carmustine; D011241:Prednisone